<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:04:54Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5441753" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5441753</identifier><datestamp>2017-05-24</datestamp><setSpec>acssd</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="rapid-communication" xml:lang="EN">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Chem</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Med. Chem</journal-id>
      <journal-id journal-id-type="publisher-id">jm</journal-id>
      <journal-id journal-id-type="coden">jmcmar</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medicinal Chemistry</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-2623</issn>
      <issn pub-type="epub">1520-4804</issn>
      <publisher>
        <publisher-name>American Chemical
Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5441753</article-id>
      <article-id pub-id-type="pmcid">PMC5441753</article-id>
      <article-id pub-id-type="pmc-uid">5441753</article-id>
      <article-id pub-id-type="pmid">28437106</article-id>
      <article-id pub-id-type="doi">10.1021/acs.jmedchem.7b00147</article-id>
      <article-categories>
        <subj-group>
          <subject>Brief Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Allosteric Targeting
of the Fanconi Anemia Ubiquitin-Conjugating
Enzyme Ube2T by Fragment Screening</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="ath1">
          <name>
            <surname>Morreale</surname>
            <given-names>Francesca
E.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">â </xref>
        </contrib>
        <contrib contrib-type="author" id="ath2">
          <name>
            <surname>Bortoluzzi</surname>
            <given-names>Alessio</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">â¡</xref>
        </contrib>
        <contrib contrib-type="author" id="ath3">
          <name>
            <surname>Chaugule</surname>
            <given-names>Viduth K.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">â </xref>
        </contrib>
        <contrib contrib-type="author" id="ath4">
          <name>
            <surname>Arkinson</surname>
            <given-names>Connor</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">â </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="ath5">
          <name>
            <surname>Walden</surname>
            <given-names>Helen</given-names>
          </name>
          <xref rid="cor1" ref-type="other">*</xref>
          <xref rid="aff1" ref-type="aff">â </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="ath6">
          <name>
            <surname>Ciulli</surname>
            <given-names>Alessio</given-names>
          </name>
          <xref rid="cor2" ref-type="other">*</xref>
          <xref rid="aff2" ref-type="aff">â¡</xref>
        </contrib>
        <aff id="aff1"><label>â </label>MRC
Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, <institution>University of Dundee</institution>, Dundee DD1 5EH, <country>United Kingdom</country></aff>
        <aff id="aff2"><label>â¡</label>Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, <institution>University of Dundee</institution>, Dundee DD1 5EH, <country>United
Kingdom</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor2"><label>*</label>For A.C.: phone, <phone>+441382386230</phone>; fax, <fax>+441382386373</fax>; e-mail, <email>a.ciulli@dundee.ac.uk</email>.</corresp>
        <corresp id="cor1"><label>*</label> H.W.: e-mail: <email>h.walden@dundee.ac.uk</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>04</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>11</day>
        <month>05</month>
        <year>2017</year>
      </pub-date>
      <volume>60</volume>
      <issue>9</issue>
      <fpage>4093</fpage>
      <lpage>4098</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>01</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2017 American Chemical
Society</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>American Chemical
Society</copyright-holder>
        <license>
          <license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p content-type="toc-graphic">
          <graphic xlink:href="jm-2017-00147m_0004" id="ab-tgr1"/>
        </p>
        <p>Ube2T is the E2 ubiquitin-conjugating
enzyme of the Fanconi anemia
DNA repair pathway and it is overexpressed in several cancers, representing
an attractive target for the development of inhibitors. Despite the
extensive efforts in targeting the ubiquitin system, very few E2 binders
have currently been discovered. Herein we report the identification
of a new allosteric pocket on Ube2T through a fragment screening using
biophysical methods. Several fragments binding to this site inhibit
ubiquitin conjugation in vitro.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>document-id-old-9</meta-name>
          <meta-value>jm7b00147</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>document-id-new-14</meta-name>
          <meta-value>jm-2017-00147m</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>ccc-price</meta-name>
          <meta-value/>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p>Ubiquitination is a
post-translational modification of proteins
that regulates many cellular processes, from protein degradation to
cell cycle progression and DNA repair.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Ubiquitin conjugation
to substrate proteins is catalyzed by the sequential action of three
enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating
enzyme), and E3 (ubiquitin ligase).<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> There
are approximately 40 known E2s in humans that regulate diverse biological
processes, making them attractive drug targets.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> Structural
information is available for many E2s, but the lack of deep active
site clefts and the need to target the protein surface have led to
E2s being considered challenging targets to small molecules.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> Indeed, to date, the possibility of targeting E2s with small molecules
has been largely unexplored and very few inhibitors are known.<sup><xref ref-type="bibr" rid="ref7">7</xref>â<xref ref-type="bibr" rid="ref10">10</xref></sup></p>
      <p>Ube2T is
the E2 enzyme of the Fanconi anemia (FA) pathway,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> which is essential for the repair of DNA interstrand
cross-links. Together with FANCL (the E3 ligase), Ube2T catalyzes
the monoubiquitination of the heterodimeric FANCI/FANCD2 complex,
which is the key signaling event to activate the FA pathway for DNA
repair.<sup><xref ref-type="bibr" rid="ref11">11</xref>â<xref ref-type="bibr" rid="ref14">14</xref></sup> Modulation of DNA repair pathways is an emerging strategy for the
development of inhibitors of tumor cell growth, as it can either potentiate
the effects of radiotherapy and conventional genotoxins or exploit
synthetic lethal interactions.<sup><xref ref-type="bibr" rid="ref15">15</xref>â<xref ref-type="bibr" rid="ref17">17</xref></sup> The latter approach relies on
genetic defects in DNA repair pathways in certain tumor cells, which
lead to hypersensitivity toward inhibitors of compensatory pathways.</p>
      <p>Ube2T has recently been found to be overexpressed in several tumors,<sup><xref ref-type="bibr" rid="ref18">18</xref>â<xref ref-type="bibr" rid="ref21">21</xref></sup> including breast<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> and prostate cancer,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> and therefore it represents an attractive therapeutic
target. Here we unveil an allosteric pocket on Ube2T that is ligandable
to small molecules as identified via fragment screening using biophysical
methods. Fragment-based drug discovery is now an established approach
for the development of lead compounds.<sup><xref ref-type="bibr" rid="ref22">22</xref>â<xref ref-type="bibr" rid="ref25">25</xref></sup> âFragmentsâ are
low molecular weight compounds (typically &lt;250â300 Da),
which bind to the target protein with weak affinities (high micromolar
to low millimolar range). Fragments represent synthetically tractable
starting points for medicinal chemistry to aid their elaboration into
high affinity small molecules.<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> The weak affinities
typically observed for fragments make it challenging to reliably detect
and validate their binding. However, direct binding methods can aid
detection of novel, secondary, and potentially allosteric sites on
protein surfaces.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> One way to enhance
success rates is to deploy a combination or cascade of biophysical
methods in order to complement the different detection and sensitivity
capabilities of the single techniques.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup></p>
    </sec>
    <sec id="sec2">
      <title>Results and Discussion</title>
      <p>Our biophysical cascade consisted of a first screen of a library
of approximately 1200 fragments using two orthogonal techniques: differential
scanning fluorimetry (DSF) and biolayer interferometry (BLI). This
was followed by a secondary screen using one-dimensional <sup>1</sup>H NMR spectroscopy, binding site identification through protein-observed
NMR spectroscopy, and X-ray crystallography.</p>
      <p>DSF monitors the
unfolding temperature of a protein using a fluorescent
dye. We screened our fragment library measuring the effect of fragments
as singletons on the melting temperature of Ube2T (Î<italic>T</italic><sub>m</sub> = <italic>T</italic><sub>mÂ Ube2T+fragment</sub> â <italic>T</italic><sub>mÂ Ube2T</sub>; Supporting Information
(SI) <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S1</ext-link>). We selected as primary
hits nine fragments that induced stabilization of the protein (Î<italic>T</italic><sub>m</sub> â¥ + 0.5 Â°C) as well as 33 fragments
that generated significant negative shifts (Î<italic>T</italic><sub>m</sub> â¤ â2.5 Â°C). Previous work has indeed
demonstrated that several destabilizers can be confirmed as real binders.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> In parallel, we screened the fragment library
using BLI, an optical technique that requires immobilization of the
target protein on a biosensor surface. Biotin-labeled Ube2T was attached
to streptavidin-coated biosensors and screened against the fragment
library at a concentration of 200 Î¼M. A total of 90 fragments
gave a statistically significant response in BLI (above a threshold
value calculated as the sum of the robust standard deviation multiplied
by three and the median). Interestingly, most of these 90 BLI hits
caused negative Î<italic>T</italic><sub>m</sub> in the DSF screening
(SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S2</ext-link>). We then repeated the BLI
experiment with the 90 fragments using a six-point concentration series,
and 37 hits were selected after visual inspection of the individual
binding sensograms. As a result of this first screen, we obtained
42 DSF hits (nine stabilizers and 33 destabilizers) and 37 BLI hits,
out of which 10 were in common between the two screens (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S3A</ext-link>), making a total of 69 unique hits
(5.5% overall hit rate).</p>
      <p>Of these initial hits, 34 fragments
were chosen based on chemical
diversity and commercial availability and submitted to a series of
one-dimensional <sup>1</sup>H NMR spectroscopy binding experiments:
water ligand observed gradient spectroscopy (WaterLOGSY),<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> saturation transfer difference (STD),<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> and CarrâPurcellâMeiboomâGill
(CPMG)<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> relaxation-edited sequences. Binding was
assessed by comparing the proton signals of the fragments in the presence
and in the absence of the protein. This secondary screen validated
13 of the 34 hits identified in the primary screen (61.8% attrition
rate).</p>
      <p>The next goal was the identification of fragmentsâ
binding
sites on the Ube2T surface. X-ray crystallography is normally the
method of choice for investigating the molecular details of proteinâligand
interactions. Proteinâfragment complexes are frequently obtained
by soaking high-concentration solutions of fragments into apo protein
crystals, however, this method has some limitations. Poor solubility
and weak affinities of fragments can hamper the obtainment of cocrystal
structures with high bound fragment occupancy. Furthermore, targeted
pockets may be occluded by crystal packing contacts and limited structural
rearrangement can occur without damaging the apo protein crystals,
often preventing the identification of cryptic pockets. For the above
reasons, we first used protein-observed NMR spectroscopy in solution
to map the binding sites.</p>
      <p>We expressed a truncated form of Ube2T
(Ube2T<sub>1â154</sub>, lacking the C-terminal flexible tail),<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> assigned the backbone amide protons of the HSQC
spectrum (BMRB entry
27035), and performed chemical shift perturbation (CSP) analysis with
each individual fragment. Out of the 13 fragments, six induced detectable
shifts at 2 mM concentration after visual inspection of the spectra
(the six validated binders were equally distributed between BLI and
DSF hits; a summary of the confirmed hits is shown in SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S3</ext-link>, together with some representative
data). CSPs shown by the six fragments were concentration-dependent,
as demonstrated by a four-point titration of fragment into protein
(SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S4</ext-link>).</p>
      <p>Shifts mapped onto
the X-ray structures of Ube2T (PDB 1YH2,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> 4CCG<sup><xref ref-type="bibr" rid="ref36">36</xref></sup>) were primarily clustered
around a pocket adjacent to the catalytic cysteine (Cys86), formed
by the loop between strand Î²4 and the 3<sub>10</sub> helix of
the E2 fold (<xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref> and <xref rid="fig2" ref-type="fig">2</xref>A). A slightly different behavior was
observed for EM02 and EM17 (to a lesser extent), which also shifted
several amino acids located between strands Î²1 and Î²2
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A,E).</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Chemical shift
perturbations observed upon addition of 3 mM fragment*
to 80 Î¼M Ube2T<sub>1â154</sub>. Weighted ÎÎ´s
â¥ average + SD are indicated by a yellow line. Weighted ÎÎ´s
â¥ average + 2 Ã SD are indicated by an orange line. Equivalent
colors are used to highlight corresponding residues on the Ube2T surface.
As a reference, the catalytic cysteine (C86) is colored in green.
Chemical structures for individual fragments are shown. For HSQC spectra
and weighted ÎÎ´s formula, see <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">SI</ext-link>. *Concentration accuracy is limited by solubility issues for several
fragments.</p>
        </caption>
        <graphic xlink:href="jm-2017-00147m_0001" id="gr1" position="float"/>
      </fig>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Crystal structure of EM04 in complex with Ube2T.
(A) EM04-bound
Ube2T structure (PDB 5NGZ) showing 2<italic>F</italic><sub>o</sub> â <italic>F</italic><sub>c</sub> electron density map contoured at 0.9Ï level for
fragment EM04. Amino acid side chains in the EM04 binding site are
shown as ball and sticks and colored in orange and yellow consistent
with the results of the CSP experiments, as described in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. (B) Zoom-in of
the fragmentâs binding pocket. Hydrogen bonds are represented
as dotted yellow lines.</p>
        </caption>
        <graphic xlink:href="jm-2017-00147m_0002" id="gr2" position="float"/>
      </fig>
      <p>To elucidate the fragments binding modes, we next obtained
well-diffracting
protein crystals (1.7 Ã for the apo form) that we found to tolerate
relatively high concentrations of organic solvents that are needed
for fragment soaking. The binding site identified by protein NMR was
found to be solvent-accessible in our crystal form, suggesting that
it would be suitable for soaking experiments. We could confirm this
by solving the crystal structure of Ube2T in complex with EM04 at
2.4 Ã resolution (PDB 5NGZ, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S5</ext-link>). The newly discovered
pocket is distinct from the small molecules binding sites identified
on the E2s Cdc34 and Ubc9 (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S6</ext-link>).</p>
      <p>EM04 binds Ube2T with a <italic>K</italic><sub>D</sub> =
1.3 mM
(LE = 0.36 kcal mol<sup>â1</sup>), as measured by isothermal
titration calorimetry (ITC) (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S7A</ext-link>). As shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B, the binding mode is driven by several hydrophobic contacts and
by a hydrogen bond between the amino group of EM04 and the carbonyl
group of Phe70 on Ube2T. An âNH<sub>2</sub> (hydrogen bond
donor) appears to be a common structural feature between the identified
fragments, as it is also present in EM02, EM11, EM17, and EM29, potentially
suggesting a conserved interaction. A second hydrogen bond is formed
between the backbone NH of Ile74 and the sulfur atom of the benzothiazole
ring. These data are in agreement with the CSP experiments, where
major shifts were observed for Ile74 backbone NH upon fragment addition
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B and SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S4</ext-link>).</p>
      <p>Fragments are typically thought
as too weak binders to warrant
testing in functional assays. However, fragments binding to secondary
pockets have been found to exert allosteric effects on their targets.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> To address this, we next investigated whether the validated fragments
could impact Ube2T enzymatic activity using a biochemical assay, which
measures the conjugation of fluorescently labeled ubiquitin to the
substrate protein FANCD2.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> A significant
reduction of substrate ubiquitination was observed upon addition of
fragments EM02, EM04, and EM17 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A), suggesting that binding of small molecules to this
pocket can lead to inhibition of Ube2Tâs biochemical activity.
The assay was repeated in the presence of detergent as a control for
aggregation (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S8</ext-link>). None of the
fragments affected the formation of the Ube2Tâubiquitin thioester
(as demonstrated by an E2-charging assay, SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S9</ext-link>), suggesting that such inhibition involves the catalytic
transfer of the thioester-linked ubiquitin molecule from Ube2T to
the substrate protein FANCD2. The effect of EM02, EM04, and EM17 on
FANCD2 ubiquitination was concentration-dependent (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B) as shown by a four-point
titration series. Additionally, the three fragments did not show detectable
inhibitory effect when tested in a similar biochemical assay set up
using UbcH5c as ubiquitin-conjugating enzyme (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S10</ext-link>), suggesting that selectivity toward Ube2T can
be achieved.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Fragments inhibit substrate ubiquitination by Ube2T. (A)
Effect
of the six fragments at 2.5 mM on Ube2T-mediated FANCD2 ubiquitination.
A representative fluorescence scan shows the levels of monoubiquitinated
FANCD2 using fluorescently labeled ubiquitin. The additional assays
components (E1, Ube2T, FANCL) are not shown. The bar chart shows the
integrated intensities of monoubiquitinated FANCD2 from three independent
experiments normalized to DMSO reactions and plotted as mean Â±
SEM. (B) Concentration-dependent effect of fragments EM02, EM04, and
EM17 in a four-point titration series. Representative fluorescence
scans are shown and integrated intensities from three independent
experiments are normalized to DMSO reactions and plotted as mean Â±
range. (C) Effect of 2.5 mM EM02, EM04, and EM17 on FANCD2 ubiquitination
using Ube2T P73K mutant in the assay. A representative fluorescence
scan is shown, and integrated intensities from four independent experiments
are normalized to wild type Ube2T-DMSO reactions and plotted as mean
Â± SEM. Statistical significance was determined by one-way analysis
of variance with Dunnettâs multiple-comparison test. (<italic>n</italic> = 3 or 4, ****<italic>P</italic> â¤ 0.0001, ***<italic>P</italic> â¤ 0.001, **<italic>P</italic> â¤ 0.01, *<italic>P</italic> â¤ 0.05, <italic>ns</italic><italic>P</italic> &gt;
0.05).</p>
        </caption>
        <graphic xlink:href="jm-2017-00147m_0003" id="gr3" position="float"/>
      </fig>
      <p>To further confirm that the observed
reduction in substrate ubiquitination
is due to binding to the newly identified pocket, we introduced a
point mutation on Ube2T (P73K), disrupting EM04 binding as measured
by ITC (SI, <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">Figure S7B</ext-link>). Such mutation
abolished the effect of fragments EM04 and EM17, while EM02 still
retained its inhibitory activity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C). These results validate EM04 binding site
as responsible for Ube2T inhibition. It is worth noting that Ube2T
P73K was less active compared to the wild-type protein (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C), further suggesting the
importance of this site for Ube2T function. Our data suggests a different
mechanism of action for EM02, which exhibited a different pattern
in CSPs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A)
and is the subject of current investigation in our laboratories.</p>
    </sec>
    <sec id="sec3">
      <title>Conclusions</title>
      <p>In summary, using fragment screening, we discovered a new allosteric
pocket on Ube2T, the E2 ubiquitin-conjugating enzyme of the FA pathway.
Small molecules binding to this site can inhibit substrate ubiquitination
in vitro, suggesting an allosteric modulation of Ube2T enzymatic activity,
although we cannot rule out potential direct inhibition of specific
proteinâprotein interactions. A cascade of biophysical methods
was successfully implemented to screen and validate the binding of
fragment-like small molecules and to elucidate their binding mode.
Such fragments represent attractive starting points for further elaboration
into high affinity inhibitors. A potent Ube2T inhibitor could find
application in sensitizing cancer cells to cross-linking agents (such
as cysplatin and mitomycin C) or be used to exploit specific synthetic
lethal interactions. Very few E2 inhibitors are known to date, and
targeting this newly discovered allosteric pocket could represent
a successful strategy to develop high-affinity small molecules to
effectively drug this class of enzymes.</p>
    </sec>
  </body>
  <back>
    <notes id="notes-1" notes-type="si">
      <title>Supporting Information Available</title>
      <p>The Supporting Information
is available free of charge on the <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00147">10.1021/acs.jmedchem.7b00147</ext-link>.<list id="silist" list-type="simple"><list-item><p>Experimental section:
protein expression and purification,
DSF, BLI, ligand-observed NMR spectroscopy, Ube2T backbone resonance
assignment, CSP experiments, ITC, crystallization and structure determination,
ubiquitination assays (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b00147/suppl_file/jm7b00147_si_002.csv">CSV</ext-link>)</p></list-item></list></p>
    </notes>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="sifile1">
        <media xlink:href="jm7b00147_si_001.pdf">
          <caption>
            <p>jm7b00147_si_001.pdf</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="sifile2">
        <media xlink:href="jm7b00147_si_002.csv">
          <caption>
            <p>jm7b00147_si_002.csv</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <notes id="notes-2" notes-type="accession-codes">
      <title>Accession Codes</title>
      <p>Atomic coordinates
can be accessed using PDB code 5NGZ. Authors will release the atomic coordinates
and experimental data upon article publication. Backbone assignment
of human Ube2T(1â154) can be accessed using BMRB accession
number 27035.</p>
    </notes>
    <notes id="NOTES-d46e563-autogenerated" notes-type="COI-statement">
      <p>The authors declare no
competing financial interest.</p>
    </notes>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported
by the European Research Council (ERC-2012-StG-311460
DrugE3CRLs starting grant to A.C.; ERC-2015-CoG-681582 ICLUb consolidator
grant to H.W.); the UK Biotechnology and Biological Sciences Research
Council (BBSRC BB/G023123/2 David Phillips Fellowship to A.C.); the
Medical Research Council (MRC grant number MC_UU_12016/12); the EMBO
Young Investigator Programme to H.W.; and the Wellcome Trust (strategic
awards 100476/Z/12/Z for biophysics and drug discovery and 094090/Z/10/Z
for structural biology and X-ray crystallography to BCDD). We thank
D. Robinson (Drug Discovery Unit, University of Dundee) for providing
access to fragment libraries and R. T. Hay (University of Dundee)
for sharing the cDNA construct for 6xHis-MBP-RNF4 RING fusion protein.
We thank the Diamond Light Source for beamtime (BAG proposal MX10071)
and beamline support at beamline I04-1.</p>
    </ack>
    <glossary id="dl1">
      <def-list>
        <title>Abbreviations Used</title>
        <def-item>
          <term>FA</term>
          <def>
            <p>Fanconi anemia</p>
          </def>
        </def-item>
        <def-item>
          <term>DSF</term>
          <def>
            <p>differential scanning fluorimetry</p>
          </def>
        </def-item>
        <def-item>
          <term>BLI</term>
          <def>
            <p>biolayer interferometry</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p>standard deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>WaterLOGSY</term>
          <def>
            <p>water ligand
observed gradient spectroscopy</p>
          </def>
        </def-item>
        <def-item>
          <term>STD</term>
          <def>
            <p>saturation transfer difference</p>
          </def>
        </def-item>
        <def-item>
          <term>CPMG</term>
          <def>
            <p>CarrâPurcellâMeiboomâGill</p>
          </def>
        </def-item>
        <def-item>
          <term>CSP</term>
          <def>
            <p>chemical shift
perturbation</p>
          </def>
        </def-item>
        <def-item>
          <term>ITC</term>
          <def>
            <p>isothermal titration calorimetry</p>
          </def>
        </def-item>
        <def-item>
          <term>SEM</term>
          <def>
            <p>standard errors of the mean</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <mixed-citation publication-type="journal" id="cit1"><name><surname>Pickart</surname><given-names>C. M.</given-names></name>; <name><surname>Eddins</surname><given-names>M. J.</given-names></name>
<article-title>Ubiquitin: structures, functions, mechanisms</article-title>. <source>Biochim. Biophys. Acta, Mol. Cell Res.</source>
<year>2004</year>, <volume>1695</volume>, <fpage>55</fpage>â<lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2004.09.019</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation publication-type="journal" id="cit2"><name><surname>Welchman</surname><given-names>R. L.</given-names></name>; <name><surname>Gordon</surname><given-names>C.</given-names></name>; <name><surname>Mayer</surname><given-names>R. J.</given-names></name>
<article-title>Ubiquitin
and ubiquitin-like proteins
as multifunctional signals</article-title>. <source>Nat. Rev. Mol. Cell
Biol.</source>
<year>2005</year>, <volume>6</volume>, <fpage>599</fpage>â<lpage>609</lpage><pub-id pub-id-type="doi">10.1038/nrm1700</pub-id>.<pub-id pub-id-type="pmid">16064136</pub-id></mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation publication-type="journal" id="cit3"><name><surname>Dye</surname><given-names>B. T.</given-names></name>; <name><surname>Schulman</surname><given-names>B. A.</given-names></name>
<article-title>Structural mechanisms
underlying posttranslational
modification by ubiquitin-like proteins</article-title>. <source>Annu.
Rev. Biophys. Biomol. Struct.</source>
<year>2007</year>, <volume>36</volume>, <fpage>131</fpage>â<lpage>150</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.36.040306.132820</pub-id>.<pub-id pub-id-type="pmid">17477837</pub-id></mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation publication-type="journal" id="cit4"><name><surname>van
Wijk</surname><given-names>S. J.</given-names></name>; <name><surname>Timmers</surname><given-names>H. T.</given-names></name>
<article-title>The family of ubiquitin-conjugating
enzymes (E2s): deciding between life and death of proteins</article-title>. <source>FASEB J.</source>
<year>2010</year>, <volume>24</volume>, <fpage>981</fpage>â<lpage>993</lpage><pub-id pub-id-type="doi">10.1096/fj.09-136259</pub-id>.<pub-id pub-id-type="pmid">19940261</pub-id></mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation publication-type="journal" id="cit5"><name><surname>Stewart</surname><given-names>M. D.</given-names></name>; <name><surname>Ritterhoff</surname><given-names>T.</given-names></name>; <name><surname>Klevit</surname><given-names>R. E.</given-names></name>; <name><surname>Brzovic</surname><given-names>P. S.</given-names></name>
<article-title>E2 enzymes: more
than just middle men</article-title>. <source>Cell Res.</source>
<year>2016</year>, <volume>26</volume>, <fpage>423</fpage>â<lpage>440</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.35</pub-id>.<pub-id pub-id-type="pmid">27002219</pub-id></mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation publication-type="journal" id="cit6"><name><surname>Sheng</surname><given-names>Y.</given-names></name>; <name><surname>Hong</surname><given-names>J. H.</given-names></name>; <name><surname>Doherty</surname><given-names>R.</given-names></name>; <name><surname>Srikumar</surname><given-names>T.</given-names></name>; <name><surname>Shloush</surname><given-names>J.</given-names></name>; <name><surname>Avvakumov</surname><given-names>G. V.</given-names></name>; <name><surname>Walker</surname><given-names>J. R.</given-names></name>; <name><surname>Xue</surname><given-names>S.</given-names></name>; <name><surname>Neculai</surname><given-names>D.</given-names></name>; <name><surname>Wan</surname><given-names>J. W.</given-names></name>; <name><surname>Kim</surname><given-names>S. K.</given-names></name>; <name><surname>Arrowsmith</surname><given-names>C. H.</given-names></name>; <name><surname>Raught</surname><given-names>B.</given-names></name>; <name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name>
<article-title>A human ubiquitin
conjugating enzyme
(E2)-HECT E3 ligase structure-function screen</article-title>. <source>Mol. Cell. Proteomics</source>
<year>2012</year>, <volume>11</volume>, <fpage>329</fpage>â<lpage>341</lpage><pub-id pub-id-type="doi">10.1074/mcp.O111.013706</pub-id>.<pub-id pub-id-type="pmid">22496338</pub-id></mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation publication-type="journal" id="cit7"><name><surname>Ceccarelli</surname><given-names>D. F.</given-names></name>; <name><surname>Tang</surname><given-names>X.</given-names></name>; <name><surname>Pelletier</surname><given-names>B.</given-names></name>; <name><surname>Orlicky</surname><given-names>S.</given-names></name>; <name><surname>Xie</surname><given-names>W.</given-names></name>; <name><surname>Plantevin</surname><given-names>V.</given-names></name>; <name><surname>Neculai</surname><given-names>D.</given-names></name>; <name><surname>Chou</surname><given-names>Y. C.</given-names></name>; <name><surname>Ogunjimi</surname><given-names>A.</given-names></name>; <name><surname>Al-Hakim</surname><given-names>A.</given-names></name>; <name><surname>Varelas</surname><given-names>X.</given-names></name>; <name><surname>Koszela</surname><given-names>J.</given-names></name>; <name><surname>Wasney</surname><given-names>G. A.</given-names></name>; <name><surname>Vedadi</surname><given-names>M.</given-names></name>; <name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name>; <name><surname>Cox</surname><given-names>S.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>; <name><surname>Lopez-Girona</surname><given-names>A.</given-names></name>; <name><surname>Mercurio</surname><given-names>F.</given-names></name>; <name><surname>Wrana</surname><given-names>J.</given-names></name>; <name><surname>Durocher</surname><given-names>D.</given-names></name>; <name><surname>Meloche</surname><given-names>S.</given-names></name>; <name><surname>Webb</surname><given-names>D. R.</given-names></name>; <name><surname>Tyers</surname><given-names>M.</given-names></name>; <name><surname>Sicheri</surname><given-names>F.</given-names></name>
<article-title>An allosteric
inhibitor of the human Cdc34 ubiquitin-conjugating enzyme</article-title>. <source>Cell</source>
<year>2011</year>, <volume>145</volume>, <fpage>1075</fpage>â<lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.05.039</pub-id>.<pub-id pub-id-type="pmid">21683433</pub-id></mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation publication-type="journal" id="cit8"><name><surname>Hewitt</surname><given-names>W. M.</given-names></name>; <name><surname>Lountos</surname><given-names>G. T.</given-names></name>; <name><surname>Zlotkowski</surname><given-names>K.</given-names></name>; <name><surname>Dahlhauser</surname><given-names>S. D.</given-names></name>; <name><surname>Saunders</surname><given-names>L. B.</given-names></name>; <name><surname>Needle</surname><given-names>D.</given-names></name>; <name><surname>Tropea</surname><given-names>J. E.</given-names></name>; <name><surname>Zhan</surname><given-names>C.</given-names></name>; <name><surname>Wei</surname><given-names>G.</given-names></name>; <name><surname>Ma</surname><given-names>B.</given-names></name>; <name><surname>Nussinov</surname><given-names>R.</given-names></name>; <name><surname>Waugh</surname><given-names>D. S.</given-names></name>; <name><surname>Schneekloth</surname><given-names>J. S.</given-names><suffix>Jr.</suffix></name>
<article-title>Insights into the allosteric inhibition of the SUMO
E2 enzyme Ubc9</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2016</year>, <volume>55</volume>, <fpage>5703</fpage>â<lpage>5707</lpage><pub-id pub-id-type="doi">10.1002/anie.201511351</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation publication-type="journal" id="cit9"><name><surname>Hodge</surname><given-names>C. D.</given-names></name>; <name><surname>Edwards</surname><given-names>R. A.</given-names></name>; <name><surname>Markin</surname><given-names>C. J.</given-names></name>; <name><surname>McDonald</surname><given-names>D.</given-names></name>; <name><surname>Pulvino</surname><given-names>M.</given-names></name>; <name><surname>Huen</surname><given-names>M. S.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Spyracopoulos</surname><given-names>L.</given-names></name>; <name><surname>Hendzel</surname><given-names>M. J.</given-names></name>; <name><surname>Glover</surname><given-names>J. N.</given-names></name>
<article-title>Covalent inhibition
of Ubc13 affects
ubiquitin signaling and reveals active site elements important for
targeting</article-title>. <source>ACS Chem. Biol.</source>
<year>2015</year>, <volume>10</volume>, <fpage>1718</fpage>â<lpage>1728</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00222</pub-id>.<pub-id pub-id-type="pmid">25909880</pub-id></mixed-citation>
      </ref>
      <ref id="ref10">
        <mixed-citation publication-type="journal" id="cit10"><name><surname>Strickson</surname><given-names>S.</given-names></name>; <name><surname>Campbell</surname><given-names>D. G.</given-names></name>; <name><surname>Emmerich</surname><given-names>C. H.</given-names></name>; <name><surname>Knebel</surname><given-names>A.</given-names></name>; <name><surname>Plater</surname><given-names>L.</given-names></name>; <name><surname>Ritorto</surname><given-names>M. S.</given-names></name>; <name><surname>Shpiro</surname><given-names>N.</given-names></name>; <name><surname>Cohen</surname><given-names>P.</given-names></name>
<article-title>The anti-inflammatory
drug BAY 11â7082 suppresses the MyD88-dependent signalling
network by targeting the ubiquitin system</article-title>. <source>Biochem.
J.</source>
<year>2013</year>, <volume>451</volume>, <fpage>427</fpage>â<lpage>437</lpage><pub-id pub-id-type="doi">10.1042/BJ20121651</pub-id>.<pub-id pub-id-type="pmid">23441730</pub-id></mixed-citation>
      </ref>
      <ref id="ref11">
        <mixed-citation publication-type="journal" id="cit11"><name><surname>Machida</surname><given-names>Y.
J.</given-names></name>; <name><surname>Machida</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Gurtan</surname><given-names>A. M.</given-names></name>; <name><surname>Kupfer</surname><given-names>G. M.</given-names></name>; <name><surname>DâAndrea</surname><given-names>A. D.</given-names></name>; <name><surname>Dutta</surname><given-names>A.</given-names></name>
<article-title>UBE2T is the E2 in the Fanconi anemia
pathway and undergoes negative autoregulation</article-title>. <source>Mol. Cell</source>
<year>2006</year>, <volume>23</volume>, <fpage>589</fpage>â<lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.06.024</pub-id>.<pub-id pub-id-type="pmid">16916645</pub-id></mixed-citation>
      </ref>
      <ref id="ref12">
        <mixed-citation publication-type="journal" id="cit12"><name><surname>Alpi</surname><given-names>A.</given-names></name>; <name><surname>Langevin</surname><given-names>F.</given-names></name>; <name><surname>Mosedale</surname><given-names>G.</given-names></name>; <name><surname>Machida</surname><given-names>Y. J.</given-names></name>; <name><surname>Dutta</surname><given-names>A.</given-names></name>; <name><surname>Patel</surname><given-names>K. J.</given-names></name>
<article-title>UBE2T, the Fanconi anemia core complex, and FANCD2
are recruited independently to chromatin: a basis for the regulation
of FANCD2 monoubiquitination</article-title>. <source>Mol. Cell. Biol.</source>
<year>2007</year>, <volume>27</volume>, <fpage>8421</fpage>â<lpage>8430</lpage><pub-id pub-id-type="doi">10.1128/MCB.00504-07</pub-id>.<pub-id pub-id-type="pmid">17938197</pub-id></mixed-citation>
      </ref>
      <ref id="ref13">
        <mixed-citation publication-type="journal" id="cit13"><name><surname>Alpi</surname><given-names>A. F.</given-names></name>; <name><surname>Pace</surname><given-names>P. E.</given-names></name>; <name><surname>Babu</surname><given-names>M. M.</given-names></name>; <name><surname>Patel</surname><given-names>K. J.</given-names></name>
<article-title>Mechanistic insight
into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL,
and FANCI</article-title>. <source>Mol. Cell</source>
<year>2008</year>, <volume>32</volume>, <fpage>767</fpage>â<lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.12.003</pub-id>.<pub-id pub-id-type="pmid">19111657</pub-id></mixed-citation>
      </ref>
      <ref id="ref14">
        <mixed-citation publication-type="journal" id="cit14"><name><surname>Walden</surname><given-names>H.</given-names></name>; <name><surname>Deans</surname><given-names>A. J.</given-names></name>
<article-title>The Fanconi anemia
DNA repair pathway: structural and
functional insights into a complex disorder</article-title>. <source>Annu. Rev. Biophys.</source>
<year>2014</year>, <volume>43</volume>, <fpage>257</fpage>â<lpage>278</lpage><pub-id pub-id-type="doi">10.1146/annurev-biophys-051013-022737</pub-id>.<pub-id pub-id-type="pmid">24773018</pub-id></mixed-citation>
      </ref>
      <ref id="ref15">
        <mixed-citation publication-type="journal" id="cit15"><name><surname>Pearl</surname><given-names>L. H.</given-names></name>; <name><surname>Schierz</surname><given-names>A. C.</given-names></name>; <name><surname>Ward</surname><given-names>S. E.</given-names></name>; <name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>; <name><surname>Pearl</surname><given-names>F. M.</given-names></name>
<article-title>Therapeutic opportunities within
the DNA damage response</article-title>. <source>Nat. Rev. Cancer</source>
<year>2015</year>, <volume>15</volume>, <fpage>166</fpage>â<lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nrc3891</pub-id>.<pub-id pub-id-type="pmid">25709118</pub-id></mixed-citation>
      </ref>
      <ref id="ref16">
        <mixed-citation publication-type="journal" id="cit16"><name><surname>Curtin</surname><given-names>N. J.</given-names></name>
<article-title>DNA repair
dysregulation from cancer driver to therapeutic target</article-title>. <source>Nat. Rev. Cancer</source>
<year>2012</year>, <volume>12</volume>, <fpage>801</fpage>â<lpage>817</lpage><pub-id pub-id-type="doi">10.1038/nrc3399</pub-id>.<pub-id pub-id-type="pmid">23175119</pub-id></mixed-citation>
      </ref>
      <ref id="ref17">
        <mixed-citation publication-type="journal" id="cit17"><name><surname>Helleday</surname><given-names>T.</given-names></name>; <name><surname>Petermann</surname><given-names>E.</given-names></name>; <name><surname>Lundin</surname><given-names>C.</given-names></name>; <name><surname>Hodgson</surname><given-names>B.</given-names></name>; <name><surname>Sharma</surname><given-names>R. A.</given-names></name>
<article-title>DNA repair
pathways as targets for cancer therapy</article-title>. <source>Nat.
Rev. Cancer</source>
<year>2008</year>, <volume>8</volume>, <fpage>193</fpage>â<lpage>204</lpage><pub-id pub-id-type="doi">10.1038/nrc2342</pub-id>.<pub-id pub-id-type="pmid">18256616</pub-id></mixed-citation>
      </ref>
      <ref id="ref18">
        <mixed-citation publication-type="journal" id="cit18"><name><surname>Ueki</surname><given-names>T.</given-names></name>; <name><surname>Park</surname><given-names>J. H.</given-names></name>; <name><surname>Nishidate</surname><given-names>T.</given-names></name>; <name><surname>Kijima</surname><given-names>K.</given-names></name>; <name><surname>Hirata</surname><given-names>K.</given-names></name>; <name><surname>Nakamura</surname><given-names>Y.</given-names></name>; <name><surname>Katagiri</surname><given-names>T.</given-names></name>
<article-title>Ubiquitination
and downregulation
of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human
breast cancer cells</article-title>. <source>Cancer Res.</source>
<year>2009</year>, <volume>69</volume>, <fpage>8752</fpage>â<lpage>8760</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1809</pub-id>.<pub-id pub-id-type="pmid">19887602</pub-id></mixed-citation>
      </ref>
      <ref id="ref19">
        <mixed-citation publication-type="journal" id="cit19"><name><surname>Yu</surname><given-names>H.</given-names></name>; <name><surname>Xiang</surname><given-names>P.</given-names></name>; <name><surname>Pan</surname><given-names>Q.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Xie</surname><given-names>N.</given-names></name>; <name><surname>Zhu</surname><given-names>W.</given-names></name>
<article-title>Ubiquitin-conjugating
enzyme E2T is an independent prognostic factor
and promotes gastric cancer progression</article-title>. <source>Tumor
Biol.</source>
<year>2016</year>, <volume>37</volume>, <fpage>11723</fpage>â<lpage>11732</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5020-3</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref20">
        <mixed-citation publication-type="journal" id="cit20"><name><surname>Wen</surname><given-names>M.</given-names></name>; <name><surname>Kwon</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Mao</surname><given-names>J. H.</given-names></name>; <name><surname>Wei</surname><given-names>G.</given-names></name>
<article-title>Elevated expression
of UBE2T exhibits oncogenic properties in human prostate cancer</article-title>. <source>Oncotarget</source>
<year>2015</year>, <volume>6</volume>, <fpage>25226</fpage>â<lpage>25239</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4712</pub-id>.<pub-id pub-id-type="pmid">26308072</pub-id></mixed-citation>
      </ref>
      <ref id="ref21">
        <mixed-citation publication-type="journal" id="cit21"><name><surname>Hu</surname><given-names>W.</given-names></name>; <name><surname>Xiao</surname><given-names>L.</given-names></name>; <name><surname>Cao</surname><given-names>C.</given-names></name>; <name><surname>Hua</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>D.</given-names></name>
<article-title>UBE2T promotes
nasopharyngeal carcinoma cell proliferation, invasion, and metastasis
by activating the AKT/GSK3beta/beta-catenin pathway</article-title>. <source>Oncotarget</source>
<year>2016</year>, <volume>7</volume>, <fpage>15161</fpage>â<lpage>15172</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7805</pub-id>.<pub-id pub-id-type="pmid">26943030</pub-id></mixed-citation>
      </ref>
      <ref id="ref22">
        <mixed-citation publication-type="journal" id="cit22"><name><surname>Hajduk</surname><given-names>P. J.</given-names></name>; <name><surname>Greer</surname><given-names>J.</given-names></name>
<article-title>A decade of fragment-based drug design:
strategic advances and lessons
learned</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2007</year>, <volume>6</volume>, <fpage>211</fpage>â<lpage>219</lpage><pub-id pub-id-type="doi">10.1038/nrd2220</pub-id>.<pub-id pub-id-type="pmid">17290284</pub-id></mixed-citation>
      </ref>
      <ref id="ref23">
        <mixed-citation publication-type="journal" id="cit23"><name><surname>Murray</surname><given-names>C. W.</given-names></name>; <name><surname>Rees</surname><given-names>D. C.</given-names></name>
<article-title>The rise of fragment-based
drug discovery</article-title>. <source>Nat. Chem.</source>
<year>2009</year>, <volume>1</volume>, <fpage>187</fpage>â<lpage>192</lpage><pub-id pub-id-type="doi">10.1038/nchem.217</pub-id>.<pub-id pub-id-type="pmid">21378847</pub-id></mixed-citation>
      </ref>
      <ref id="ref24">
        <mixed-citation publication-type="journal" id="cit24"><name><surname>Scott</surname><given-names>D. E.</given-names></name>; <name><surname>Coyne</surname><given-names>A. G.</given-names></name>; <name><surname>Hudson</surname><given-names>S. A.</given-names></name>; <name><surname>Abell</surname><given-names>C.</given-names></name>
<article-title>Fragment-based approaches
in drug discovery and chemical biology</article-title>. <source>Biochemistry</source>
<year>2012</year>, <volume>51</volume>, <fpage>4990</fpage>â<lpage>5003</lpage><pub-id pub-id-type="doi">10.1021/bi3005126</pub-id>.<pub-id pub-id-type="pmid">22697260</pub-id></mixed-citation>
      </ref>
      <ref id="ref25">
        <mixed-citation publication-type="journal" id="cit25"><name><surname>Erlanson</surname><given-names>D. A.</given-names></name>; <name><surname>Fesik</surname><given-names>S. W.</given-names></name>; <name><surname>Hubbard</surname><given-names>R. E.</given-names></name>; <name><surname>Jahnke</surname><given-names>W.</given-names></name>; <name><surname>Jhoti</surname><given-names>H.</given-names></name>
<article-title>Twenty years
on: the impact of fragments on drug discovery</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2016</year>, <volume>15</volume>, <fpage>605</fpage>â<lpage>619</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.109</pub-id>.<pub-id pub-id-type="pmid">27417849</pub-id></mixed-citation>
      </ref>
      <ref id="ref26">
        <mixed-citation publication-type="journal" id="cit26"><name><surname>Chessari</surname><given-names>G.</given-names></name>; <name><surname>Woodhead</surname><given-names>A. J.</given-names></name>
<article-title>From fragment to clinical candidate--a historical perspective</article-title>. <source>Drug Discovery Today</source>
<year>2009</year>, <volume>14</volume>, <fpage>668</fpage>â<lpage>675</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2009.04.007</pub-id>.<pub-id pub-id-type="pmid">19427404</pub-id></mixed-citation>
      </ref>
      <ref id="ref27">
        <mixed-citation publication-type="journal" id="cit27"><name><surname>Baker</surname><given-names>M.</given-names></name>
<article-title>Fragment-based
lead discovery grows up</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2013</year>, <volume>12</volume>, <fpage>5</fpage>â<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nrd3926</pub-id>.<pub-id pub-id-type="pmid">23274457</pub-id></mixed-citation>
      </ref>
      <ref id="ref28">
        <mixed-citation publication-type="journal" id="cit28"><name><surname>Ludlow</surname><given-names>R. F.</given-names></name>; <name><surname>Verdonk</surname><given-names>M. L.</given-names></name>; <name><surname>Saini</surname><given-names>H. K.</given-names></name>; <name><surname>Tickle</surname><given-names>I. J.</given-names></name>; <name><surname>Jhoti</surname><given-names>H.</given-names></name>
<article-title>Detection
of secondary binding sites in proteins using fragment screening</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2015</year>, <volume>112</volume>, <fpage>15910</fpage>â<lpage>15915</lpage><pub-id pub-id-type="doi">10.1073/pnas.1518946112</pub-id>.<pub-id pub-id-type="pmid">26655740</pub-id></mixed-citation>
      </ref>
      <ref id="ref29">
        <mixed-citation publication-type="journal" id="cit29"><name><surname>Silvestre</surname><given-names>H. L.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>; <name><surname>Abell</surname><given-names>C.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>
<article-title>Integrated biophysical
approach to fragment screening and validation for fragment-based lead
discovery</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2013</year>, <volume>110</volume>, <fpage>12984</fpage>â<lpage>12989</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304045110</pub-id>.<pub-id pub-id-type="pmid">23872845</pub-id></mixed-citation>
      </ref>
      <ref id="ref30">
        <mixed-citation publication-type="journal" id="cit30"><name><surname>Renaud</surname><given-names>J. P.</given-names></name>; <name><surname>Chung</surname><given-names>C. W.</given-names></name>; <name><surname>Danielson</surname><given-names>U. H.</given-names></name>; <name><surname>Egner</surname><given-names>U.</given-names></name>; <name><surname>Hennig</surname><given-names>M.</given-names></name>; <name><surname>Hubbard</surname><given-names>R. E.</given-names></name>; <name><surname>Nar</surname><given-names>H.</given-names></name>
<article-title>Biophysics
in drug discovery: impact,
challenges and opportunities</article-title>. <source>Nat. Rev. Drug
Discovery</source>
<year>2016</year>, <volume>15</volume>, <fpage>679</fpage>â<lpage>698</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.123</pub-id>.<pub-id pub-id-type="pmid">27516170</pub-id></mixed-citation>
      </ref>
      <ref id="ref31">
        <mixed-citation publication-type="journal" id="cit31"><name><surname>Dai</surname><given-names>R.</given-names></name>; <name><surname>Geders</surname><given-names>T. W.</given-names></name>; <name><surname>Liu</surname><given-names>F.</given-names></name>; <name><surname>Park</surname><given-names>S. W.</given-names></name>; <name><surname>Schnappinger</surname><given-names>D.</given-names></name>; <name><surname>Aldrich</surname><given-names>C. C.</given-names></name>; <name><surname>Finzel</surname><given-names>B. C.</given-names></name>
<article-title>Fragment-based
exploration of binding
site flexibility in Mycobacterium tuberculosis BioA</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume>, <fpage>5208</fpage>â<lpage>5217</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00092</pub-id>.<pub-id pub-id-type="pmid">26068403</pub-id></mixed-citation>
      </ref>
      <ref id="ref32">
        <mixed-citation publication-type="journal" id="cit32"><name><surname>Dalvit</surname><given-names>C.</given-names></name>; <name><surname>Fogliatto</surname><given-names>G.</given-names></name>; <name><surname>Stewart</surname><given-names>A.</given-names></name>; <name><surname>Veronesi</surname><given-names>M.</given-names></name>; <name><surname>Stockman</surname><given-names>B.</given-names></name>
<article-title>WaterLOGSY
as a method for primary NMR screening: practical aspects and range
of applicability</article-title>. <source>J. Biomol. NMR</source>
<year>2001</year>, <volume>21</volume>, <fpage>349</fpage>â<lpage>359</lpage><pub-id pub-id-type="doi">10.1023/A:1013302231549</pub-id>.<pub-id pub-id-type="pmid">11824754</pub-id></mixed-citation>
      </ref>
      <ref id="ref33">
        <mixed-citation publication-type="journal" id="cit33"><name><surname>Mayer</surname><given-names>M.</given-names></name>; <name><surname>Meyer</surname><given-names>B.</given-names></name>
<article-title>Characterization of
ligand binding by saturation transfer difference
NMR spectroscopy</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>1999</year>, <volume>38</volume>, <fpage>1784</fpage>â<lpage>1788</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-3773(19990614)38:12&lt;1784::AID-ANIE1784&gt;3.0.CO;2-Q</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref34">
        <mixed-citation publication-type="journal" id="cit34"><name><surname>Carr</surname><given-names>H. Y.</given-names></name>; <name><surname>Purcell</surname><given-names>E. M.</given-names></name>
<article-title>Effects of diffusion
on free precession in nuclear
magnetic resonance experiments</article-title>. <source>Phys. Rev.</source>
<year>1954</year>, <volume>94</volume>, <fpage>630</fpage>â<lpage>638</lpage><pub-id pub-id-type="doi">10.1103/PhysRev.94.630</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref35">
        <mixed-citation publication-type="journal" id="cit35"><name><surname>Meiboom</surname><given-names>S.</given-names></name>; <name><surname>Gill</surname><given-names>D.</given-names></name>
<article-title>Modified spin-echo
method for measuring nuclear relaxation times</article-title>. <source>Rev. Sci. Instrum.</source>
<year>1958</year>, <volume>29</volume>, <fpage>688</fpage>â<lpage>691</lpage><pub-id pub-id-type="doi">10.1063/1.1716296</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref36">
        <mixed-citation publication-type="journal" id="cit36"><name><surname>Hodson</surname><given-names>C.</given-names></name>; <name><surname>Purkiss</surname><given-names>A.</given-names></name>; <name><surname>Miles</surname><given-names>J. A.</given-names></name>; <name><surname>Walden</surname><given-names>H.</given-names></name>
<article-title>Structure of the human
FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection</article-title>. <source>Structure</source>
<year>2014</year>, <volume>22</volume>, <fpage>337</fpage>â<lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.12.004</pub-id>.<pub-id pub-id-type="pmid">24389026</pub-id></mixed-citation>
      </ref>
      <ref id="ref37">
        <mixed-citation publication-type="journal" id="cit37"><name><surname>Saalau-Bethell</surname><given-names>S. M.</given-names></name>; <name><surname>Woodhead</surname><given-names>A. J.</given-names></name>; <name><surname>Chessari</surname><given-names>G.</given-names></name>; <name><surname>Carr</surname><given-names>M. G.</given-names></name>; <name><surname>Coyle</surname><given-names>J.</given-names></name>; <name><surname>Graham</surname><given-names>B.</given-names></name>; <name><surname>Hiscock</surname><given-names>S. D.</given-names></name>; <name><surname>Murray</surname><given-names>C. W.</given-names></name>; <name><surname>Pathuri</surname><given-names>P.</given-names></name>; <name><surname>Rich</surname><given-names>S. J.</given-names></name>; <name><surname>Richardson</surname><given-names>C. J.</given-names></name>; <name><surname>Williams</surname><given-names>P. A.</given-names></name>; <name><surname>Jhoti</surname><given-names>H.</given-names></name>
<article-title>Discovery
of an allosteric mechanism for the regulation of HCV NS3 protein function</article-title>. <source>Nat. Chem. Biol.</source>
<year>2012</year>, <volume>8</volume>, <fpage>920</fpage>â<lpage>925</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1081</pub-id>.<pub-id pub-id-type="pmid">23023261</pub-id></mixed-citation>
      </ref>
      <ref id="ref38">
        <mixed-citation publication-type="book" id="cit38"><person-group person-group-type="allauthors"><name><surname>Davies</surname><given-names>T. G.</given-names></name>; <name><surname>Jhoti</surname><given-names>H.</given-names></name>; <name><surname>Pathuri</surname><given-names>P.</given-names></name>; <name><surname>Williams</surname><given-names>G.</given-names></name></person-group><article-title>Selecting the
right targets for fragment-based drug discovery</article-title>. In <source>Fragment-Based Drug Discovery Lessons and Outlook</source>, <edition>1st</edition> ed.; <person-group person-group-type="editor"><name><surname>Erlanson</surname><given-names>D. A.</given-names></name>, <name><surname>Jahnke</surname><given-names>W.</given-names></name></person-group>, Eds.; <publisher-name>Wiley-VCH Verlag GmbH &amp; Co. KGaA</publisher-name>: <publisher-loc>Weinheim, Germany</publisher-loc>, <year>2016</year>.</mixed-citation>
      </ref>
      <ref id="ref39">
        <mixed-citation publication-type="journal" id="cit39"><name><surname>Miles</surname><given-names>J. A.</given-names></name>; <name><surname>Frost</surname><given-names>M. G.</given-names></name>; <name><surname>Carroll</surname><given-names>E.</given-names></name>; <name><surname>Rowe</surname><given-names>M. L.</given-names></name>; <name><surname>Howard</surname><given-names>M. J.</given-names></name>; <name><surname>Sidhu</surname><given-names>A.</given-names></name>; <name><surname>Chaugule</surname><given-names>V. K.</given-names></name>; <name><surname>Alpi</surname><given-names>A. F.</given-names></name>; <name><surname>Walden</surname><given-names>H.</given-names></name>
<article-title>The Fanconi
anemia DNA repair pathway is regulated by an interaction between ubiquitin
and the E2-like fold domain of FANCL</article-title>. <source>J. Biol.
Chem.</source>
<year>2015</year>, <volume>290</volume>, <fpage>20995</fpage>â<lpage>21006</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.675835</pub-id>.<pub-id pub-id-type="pmid">26149689</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>